Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director Nancy Andrews sold 573 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $292.97 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a market cap of $13.99 billion, a PE ratio of -60.41, a P/E/G ratio of 3.00 and a beta of 1.38. The company’s fifty day simple moving average is $232.83 and its 200-day simple moving average is $193.15. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $299.32.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the firm earned $3.12 earnings per share. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen raised their price target on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a report on Monday, August 10th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Robert W. Baird set a $291.00 price target on shares of Charles River Laboratories International in a research note on Thursday, August 6th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Finally, Royal Bank Of Canada raised their price target on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $255.65.

Institutional Trading of Charles River Laboratories International

Several large investors have recently added to or reduced their stakes in CRL. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at $42,000. Sfam LLC acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $43,000. Activest Wealth Management grew its position in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Geneos Wealth Management Inc. grew its position in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Charles River Laboratories International during the 4th quarter valued at about $46,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.